Insider Selling: iCAD, Inc. (NASDAQ:ICAD) Director Sells 10,000 Shares of Stock

iCAD, Inc. (NASDAQ:ICAD) Director Andy Sassine sold 10,000 shares of the stock in a transaction that occurred on Monday, September 13th. The shares were sold at an average price of $11.09, for a total value of $110,900.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

NASDAQ:ICAD opened at $10.33 on Friday. iCAD, Inc. has a 52-week low of $8.48 and a 52-week high of $21.44. The company has a market cap of $258.62 million, a price-to-earnings ratio of -29.51 and a beta of 1.12. The firm’s 50-day moving average is $12.98 and its 200-day moving average is $16.15.

iCAD (NASDAQ:ICAD) last announced its quarterly earnings data on Thursday, August 5th. The technology company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.03). iCAD had a negative return on equity of 18.86% and a negative net margin of 24.44%. The firm had revenue of $7.83 million for the quarter, compared to analyst estimates of $9.12 million. As a group, research analysts forecast that iCAD, Inc. will post -0.27 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. Altshuler Shaham Ltd acquired a new stake in shares of iCAD during the 1st quarter valued at about $45,000. Metropolitan Life Insurance Co NY boosted its holdings in iCAD by 94,542.9% during the second quarter. Metropolitan Life Insurance Co NY now owns 6,625 shares of the technology company’s stock valued at $115,000 after purchasing an additional 6,618 shares in the last quarter. Pinz Capital Management LP bought a new stake in shares of iCAD in the 1st quarter valued at approximately $117,000. Citizens Financial Group Inc RI acquired a new position in shares of iCAD in the 1st quarter worth approximately $204,000. Finally, The Manufacturers Life Insurance Company boosted its stake in iCAD by 11.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,106 shares of the technology company’s stock valued at $227,000 after buying an additional 1,384 shares in the last quarter. 51.45% of the stock is owned by institutional investors.

A number of research firms have issued reports on ICAD. Oppenheimer restated a “buy” rating and set a $24.00 price target on shares of iCAD in a report on Monday, August 30th. Zacks Investment Research cut shares of iCAD from a “buy” rating to a “hold” rating in a report on Friday, August 6th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, iCAD has an average rating of “Buy” and an average target price of $22.13.

About iCAD

iCAD, Inc is a medical technology company, which engages in the provision cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment include image analysis and workflow products. The Cancer Therapy segment consists radiation therapy products.

Read More: Do equity income investments outperform growth and income investments?

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.